

Sponsor:	IO Biotech ApS
Protocol Number:	IO102-012
EudraCT Number:	2018-000139-28
Date of Clinical Study Report:	19 May 2023

The following table and figures have been extracted from the final IO102-012 Clinical Study Report (dated 19 May 2023) and present a summary of the results of the overall survival (OS).

Secondary Endpoint: Overall Survival – Both Phases

Number of Patients (ITT Population)	Cohort A		Cohort B	
	Exp A1 ^[1] N=38	Control A2 ^[2] N=16	Exp B1 ^[3] N=39	Control B2 ^[4] N=17
No. of OS events (deaths)	24 (63.2%)	8 (50.0%)	28 (71.8%)	11 (64.7%)
Median months to event And 95% CI	19.3 [15.0 ; -]	32 [16.6 ; -]	18.3 [14.7 ; 27]	20.2 [11.1 ; -]
Kaplan Meier estimates				
At month 6	81.6%	87.5%	89.7%	100%
At month 9	76.3%	87.5%	82.1%	93.8%
At month 12	73.7%	80.8%	76.6%	68.8%
By PD-L1 expression:				
TPS <1%	-	-	N=20	N=6
No. of OS events (deaths)	-	-	17 (85.0%)	4 (66.7%)
Median months to event And 95% CI	-	-	15.5 [12.8 ; 19.1]	21.3 [9.9 ; -]
Kaplan Meier estimates				
At month 6	-	-	95.0%	100%
At month 9	-	-	80.0%	100%
At month 12	-	-	80.0%	83.3%
TPS 1-49%	-	-	N=19	N=11
No. of OS events (deaths)	-	-	11 (57.9%)	7 (63.6%)
Median months to event And 95% CI	-	-	31 [11.5 ; -]	18.6 [7.7 ; -]

Number of Patients (ITT Population)	Cohort A		Cohort B	
	Exp A1 ^[1] N=38	Control A2 ^[2] N=16	Exp B1 ^[3] N=39	Control B2 ^[4] N=17
Kaplan Meier estimates				
At month 6	-	-	84.2%	100%
At month 9	-	-	84.2%	90.0%
At month 12	-	-	73.7%	60.0%

For median months to event, missing numbers mean that these numbers could not be calculated.


[1] Exp A1 = Arm A (Phase I) + Arm A1 (Phase II)

[2] Control A2 = Arm A2 (Phase II)

[3] Exp B1 = Arm B (Phase I) + Arm B1 (Phase II)

[4] Control B2 = Arm B2 (Phase II)

Secondary Endpoint: Overall Survival – Kaplan Meier Plot – Both Phases – Cohort A



Secondary Endpoint: Overall Survival – Kaplan Meier Plot – Both Phases – Cohort B

